Summarized by Masters of Longevity from BioSpace - Funding.
CPRIT awarded $16.2 million to fund a Phase 2 trial of MT-601.

Key Takeaways
- The grant will fund a Phase 2 APOLLO study of MT-601.
- Phase 1 showed 66% objective response and durable responses.
- Safety data showed no dose-limiting toxicities or ICANS.



